CPHI annual report predicts AI to transform all processes in drug development by 2026
The first part of the influential CPHI Annual Report predicts sizeable progress ahead for AI ’ s use in pharma , as despite the wider excitement around ChatGPT and other generative AI ’ s having cooled in recent months , pharma ’ s real-world applications continue to expand . The implications go far beyond its current use and most startling of all – notwithstanding the so far limited successes – it is expected that within 10-years over 50 % of approved drugs will involve AI in their development and / or manufacturing .
The CPHI Report ’ s AI findings , which are released ahead of CPHI Barcelona , the world ’ s largest pharma event , held at Fira Barcelona ( October 24-26th , 2023 ), point to the technology having a transformational impact on all parts of drug discovery and development within the next 24-months .
Revvity unveils several nextgeneration preclinical imaging technologies to help scientists
Revvity , Inc . debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems . These new innovations include the nextgeneration IVIS ® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems . Also launching is the QuantumTM GX3 microCT structural imaging solution with increased resolution and speed for both in vivo and ex vivo imaging , designed to facilitate researchers studying disease biology or evaluating and fast-tracking therapeutic candidates . And making its global debut is the Vega ® ultrasound system , originally launched in North America in 2022 .
BioTech
BIOVOICENEWS . COM 09